INDOCO vs WINDLAS: Stock Comparison

Indoco Remedies Limited vs Windlas Biotech Ltd

Live data: 22 July 2026, 2:52 PM IST • Source: NSE and company filings

Indoco Remedies Limited is the larger company by market capitalisation. Indoco Remedies Limited shows a lower P/E and faster revenue growth, while Windlas Biotech Ltd shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Indoco Remedies Limited and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, INDOCO is more favourable on 6 of 13 scored metrics and WINDLAS on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
INDOCO is the larger company
₹2,160 Cr vs ₹1,804 Cr
P/E Ratio
INDOCO has a lower P/E
-23.83x vs 28x
P/B Ratio
INDOCO has a lower P/B
2.41x vs 3.2x
EPS
WINDLAS has higher earnings per share
₹31.5 vs ₹-10.71
Dividend Yield
WINDLAS has a higher dividend yield
0.72% vs 0.08%
Revenue Growth (TTM YoY)
INDOCO has faster revenue growth
21.9% vs 17.7%
EPS Growth (TTM YoY)
INDOCO has faster EPS growth
0% vs -2.6%
Qtr Sales Growth
INDOCO has stronger quarterly sales growth
21.9% vs 17.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricINDOCOWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricINDOCOWINDLAS
Live Price₹233.99₹873.9
Day Change-4.82%-0.75%
Volume71,68833,062
52-Week High₹336₹1,097.9
52-Week Low₹162.19₹697.4
Distance from 52W High-30.36%-20.4%

Valuation

MetricINDOCOWINDLAS
Market Cap₹2,160 Cr₹1,804 Cr
P/E Ratio-23.83x28x
P/B Ratio2.41x3.2x
EPS₹-10.71₹31.5
Book Value₹111.55₹275
Dividend Yield0.08%0.72%

Growth

MetricINDOCOWINDLAS
Revenue Growth (TTM YoY)21.9%17.7%
EPS Growth (TTM YoY)0%-2.6%
Qtr Sales Growth21.9%17.7%
Qtr Profit Growth39%-1.78%

Profitability & Leverage

MetricINDOCOWINDLAS
ROE-9.42%12.2%
ROCE0.93%15.9%
Net Margin-5.31%7.35%
Operating Margin7.68%11.6%
Debt to Equity1.16x0.06x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricINDOCOWINDLAS
Promoter Holding58.86%63.31% 1.41 pp
FII Holding1.27% 0.33 pp2.04% 1.44 pp
DII Holding17.68% 0.47 pp9.84% 1.97 pp
Public Holding22.04% 0.14 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Indoco Remedies Limited and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.